Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Fundació Hospital Universitari Vall D’Hebron-Institut De Recerca has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action involves a single distinct examiner and 1 distinct art unit. This singular focus suggests that the institution is currently pursuing a specific advancement in biotechnology through a single patent application. The concentration within one art unit indicates that the filing is being reviewed by a group specialized in biological or pharmaceutical research.
FATIMAH KHALAF MATALKAH is the busiest examiner for the portfolio, with the pending office action. This action represents the total pending workload for the company. Because the entire prosecution effort is concentrated under one examiner and one art unit, the institution's immediate success is tied to a single point of review. This centralization allows for a focused strategy in responding to the office but also means the current experience is limited to one examiner's interpretation of biotechnology standards. A successful prosecution will require a precise response to the examiner's specific findings.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DOUGHERTY, SEAN PATRICK | 1 | 74.7% | +15.7% |
| HOPKINS, SAMANTHA LAKE | 1 | 60.4% | +62.3% |
| IVICH, FERNANDO NMN | 1 | 48.7% | +69.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18709227 | SYRINGE DRIVING SYSTEMS | DOUGHERTY, SEAN PATRICK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18709227 | SYRINGE DRIVING SYSTEMS | DOUGHERTY, SEAN PATRICK | — |
| 17622303 | INTERMEDIATE FILAMENT-DERIVED PEPTIDES AND THEIR USES | HOPKINS, SAMANTHA LAKE | — |
| 17618837 | SYNTHROCYTE: ERYTHROCYTE-MIMICKING REAGENT AND FAST METHODS FOR PATHOGEN CHARACTERIZATION AND SEROLOGY TESTING | IVICH, FERNANDO NMN | — |
| Art Unit | Apps |
|---|---|
| 3791 | 1 |
| 1641 | 1 |
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18709227 | SYRINGE DRIVING SYSTEMS | DOUGHERTY, SEAN PATRICK | 3791 | §102§103 | Non-Final OA | — | Pending | May 10, 2024 |
| 17622303 | INTERMEDIATE FILAMENT-DERIVED PEPTIDES AND THEIR USES | HOPKINS, SAMANTHA LAKE | 1641 | §112 | Final Rejection | — | Pending | Dec 23, 2021 |
| 17618837 | SYNTHROCYTE: ERYTHROCYTE-MIMICKING REAGENT AND FAST METHODS FOR PATHOGEN CHARACTERIZATION AND SEROLOGY TESTING | IVICH, FERNANDO NMN | 1678 | §112 | Non-Final OA | — | Pending | Dec 13, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial